Form 4 for NTLA Intellia Therapeutics, Inc.

Accepted 2022-06-16 00:00:00 ET · period of report 2022-06-14 · accession 0001209191-22-037598 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-06-16	2022-06-14	NTLA	FORMELA JEAN FRANCOIS	Dir	A - Grant	$0.00	+5,197	7,291	+248%	$0
D	2022-06-16	2022-06-14	NTLA	FORMELA JEAN FRANCOIS	Dir	A - Grant	$0.00	+7,688	7,688	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-06-14	A	A	5,197	$0.00	7,291	D	—	—	(F1) Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
2	Derivative	Stock Option (right to buy)	2022-06-14	A	A	7,688	$0.00	7,688	D	$38.49 · — to 2032-06-13	7,688 Common Stock	(F3) The reporting person is a member of Atlas Venture Associates IX, LLC ("AVA IX LLC") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. (F2) This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.